Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib

Simple item page
dc.contributor.authorJáklová, Kateřinacs
dc.contributor.authorFeglarová, Terezacs
dc.contributor.authorRex, Simonacs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorEckschlager, Tomášcs
dc.contributor.authorHraběta, Jancs
dc.contributor.authorHodek, Petrcs
dc.contributor.authorKolárik, Matúšcs
dc.contributor.authorIndra, Radekcs
dc.coverage.issue8cs
dc.coverage.volume22cs
dc.date.accessioned2021-09-27T07:54:05Z
dc.date.available2021-09-27T07:54:05Z
dc.date.issued2021-04-30cs
dc.description.abstractA tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. Van is primarily used for the treatment of advanced or metastatic medullary thyroid cancer; however, its usage is significantly limited by side effects, particularly cardiotoxicity. One approach to minimize them is the encapsulation or binding of Van in- or onto a suitable carrier, allowing targeted delivery to tumor tissue. Herein, we constructed a nanocarrier based on apoferritin associated with Van (ApoVan). Based on the characteristics obtained by analyzing the average size, the surface zeta-potential and the polydispersive index, ApoVan nanoparticles exhibit long-term stability and maintain their morphology. Experiments have shown that ApoVan complex is relatively stable during storage. It was found that Van is gradually released from its ApoVan form into the neutral environment (pH 7.4) as well as into the acidic environment (pH 6.5). The effect of free Van and ApoVan on neuroblastoma and medullary thyroid carcinoma cell lines revealed that both forms were toxic in both used cell lines, and minimal differences between ApoVan and Van were observed. Thus, we assume that Van might not be encapsulated into the cavity of apoferritin, but instead only binds to its surface.en
dc.formattextcs
dc.format.extent1-12cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationInternational Journal of Molecular Sciences. 2021, vol. 22, issue 8, p. 1-12.en
dc.identifier.doi10.3390/ijms22084250cs
dc.identifier.issn1422-0067cs
dc.identifier.other171626cs
dc.identifier.urihttp://hdl.handle.net/11012/201670
dc.language.isoencs
dc.publisherMDPIcs
dc.relation.ispartofInternational Journal of Molecular Sciencescs
dc.relation.urihttps://www.mdpi.com/1422-0067/22/8/4250cs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1422-0067/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectvandetaniben
dc.subjectapoferritinen
dc.subjectneuroblastomaen
dc.subjectmedullary thyroid canceren
dc.subjectcancer targetingen
dc.titleApoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetaniben
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-171626en
sync.item.dbtypeVAVen
sync.item.insts2021.09.27 09:54:05en
sync.item.modts2021.09.24 16:12:29en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms2204250v2.pdf
Size:
2.2 MB
Format:
Adobe Portable Document Format
Description:
ijms2204250v2.pdf
Download
Collections
Chytré nanonástroje